Treatment with Rebetol in combination with peginterferon alfa-2b was associated with decreases in absolute CD4+ cell counts within the first 4 weeks without a reduction in CD4+ cell percentage.
Rebetol’ i ja peginterferoon alfa- 2b kombinatsioonravi seostati CD4+ rakkude absoluutarvu vähenemisega esimese 4 nädala jooksul ilma CD4+ rakkude protsentuaalse vähenemiseta.